 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 June 1997 | Volume 126 Issue 12 | Pages 955-959
Background: Diabetic patients are considered less suitable than nondiabetic patients for ß-blocker therapy because of the risk for worsened glucose and lipid metabolism and more severe hypoglycemic attacks.
Objective: To compare the metabolic and cardiovascular effects of carvedilol with those of atenolol in diabetic patients with hypertension.
Design: Randomized, double-blind, 24-week trial.
Setting: University hospital clinic.
Patients: 45 patients with non-insulin-dependent diabetes mellitus and hypertension.
Intervention: After a 4- to 6-week run-in period during which placebo was given in a single-blind manner, patients were randomly assigned to carvedilol or atenolol.
Measurements: An oral glucose tolerance test; assessment of insulin sensitivity and hormonal responses to insulin hypoglycemia; and assessment of lipid levels, blood pressure, left ventricular mass, and lipid peroxidation.
Results: Changes in systolic and diastolic blood pressure and left ventricular mass index were similar with carvedilol and atenolol (P > 0.2). Fasting plasma glucose and insulin levels decreased with carvedilol and increased with atenolol. Responses to carvedilol were greater than those to atenolol, as follows: increase in total glucose disposal, 9.54 µmol/kg of body weight per minute (95% CI, 7 to 11.9 µmol/kg per minute); decrease in plasma glucose response to oral glucose, 61 mmol/L x 180 minutes (CI, –101 to –21 mmol/L x 180 minutes); decrease in insulin response to oral glucose, 6.2 nmol/L x 180 minutes (CI, –9.8 to –2.6 nmol/L x 180 minutes); decrease in triglyceride level, 0.56 mmol/L (CI, –0.75 to –0.37 mmol/L; P < 0.001); increase in high-density lipoprotein cholesterol level, 0.13 mmol/L (CI, 0.09 to 0.17 mmol/L; P < 0.001); and decrease in lipid peroxidation, 0.25 µmol/L (CI, –0.34 to –0.16µmol/L).
Conclusions: By improving glucose and lipid metabolism and reducing lipid peroxidation, carvedilol may offer advantages in patients with diabetes and hypertension.
Author and Article Information
From the Second University of Naples, Naples, Italy.
BRIEF COMMUNICATION
Metabolic and Cardiovascular Effects of Carvedilol and Atenolol in Non-Insulin-Dependent Diabetes Mellitus and Hypertension
A Randomized, Controlled Trial
Requests for Reprints: Dario Giugliano, MD, via Emilia 1, Afragola (NA), Italy.
Current Author Addresses: Drs. Giugliano, Marfella, De Rosa, Ziccardi, and D'Onofrio: Department of Geriatrics and Metabolic Diseases, Second University of Naples, Piazza L. Miraglia, 80138 Naples, Italy.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  D. D. Schocken, E. J. Benjamin, G. C. Fonarow, H. M. Krumholz, D. Levy, G. A. Mensah, J. Narula, E. S. Shor, J. B. Young, and Y. Hong Prevention of Heart Failure: A Scientific Statement From the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group Circulation, May 13, 2008; 117(19): 2544 - 2565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P Sharp, R. Sirajuddin, and I. M Sharief Impact of Carvedilol on the Serum Lipid Profile Ann. Pharmacother., April 1, 2008; 42(4): 564 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Prisant Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory {beta}1-Blocker J. Clin. Pharmacol., February 1, 2008; 48(2): 225 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steigerwalt Management of Hypertension in Diabetic Patients With Chronic Kidney Disease Diabetes Spectr, January 1, 2008; 21(1): 30 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Albert Switching to Once-Daily Evidence-Based -Blockers in Patients With Systolic Heart Failure or Left Ventricular Dysfunction After Myocardial Infarction Crit. Care Nurse, December 1, 2007; 27(6): 62 - 72. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P.A. Sarafidis and G.L. Bakris Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control QJM, July 1, 2006; 99(7): 431 - 436. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bakris, V. Fonseca, R. E. Katholi, J. B. McGill, F. H. Messerli, R. A. Phillips, P. Raskin, J. T. Wright Jr, R. Oakes, M. A. Lukas, et al. Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension: A Randomized Controlled Trial JAMA, November 10, 2004; 292(18): 2227 - 2236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Abbott, E. Basta, and G. L. Bakris Blood Pressure Control and Nephroprotection in Diabetes J. Clin. Pharmacol., April 1, 2004; 44(4): 431 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nodari, M. Metra, A. D. Cas, and L. D. Cas Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus Eur J Heart Fail, December 1, 2003; 5(6): 803 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S.H. Bell Heart Failure: The frequent, forgotten, and often fatal complication of diabetes Diabetes Care, August 1, 2003; 26(8): 2433 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J Tangeman and J H. Patterson Extended-Release Metoprolol Succinate in Chronic Heart Failure Ann. Pharmacother., May 1, 2003; 37(5): 701 - 710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. R. Loon Diabetic Kidney Disease: Preventing Dialysis and Transplantation Clin. Diabetes, April 1, 2003; 21(2): 55 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gheorghiade, W. S. Colucci, and K. Swedberg {beta}-Blockers in Chronic Heart Failure Circulation, April 1, 2003; 107(12): 1570 - 1575. [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Marso Optimizing the diabetic formulary: beyond aspirin and insulin J. Am. Coll. Cardiol., August 21, 2002; 40(4): 652 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Refsgaard, C. Thomsen, F. Andreasen, and O. Gotzsche Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure Eur J Heart Fail, August 1, 2002; 4(4): 445 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Luna and M. N. Feinglos Drug-Induced Hyperglycemia JAMA, October 24, 2001; 286(16): 1945 - 1948. [Full Text] [PDF]
|
|
|
|
 |
|
 C. W. Yancy, M. B. Fowler, W. S. Colucci, E. M. Gilbert, M. R. Bristow, J. N. Cohn, M. A. Lukas, S. T. Young, M. Packer, and the U.S. Carvedilol Heart Failure Study Group Race and the Response to Adrenergic Blockade with Carvedilol in Patients with Chronic Heart Failure N. Engl. J. Med., May 3, 2001; 344(18): 1358 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Barzilay, C. L. Jones, B. R. Davis, J. N. Basile, D. C. Goff Jr., J. O. Ciocon, M. E. Sweeney, and O. S. Randall Baseline Characteristics of the Diabetic Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Diabetes Care, April 1, 2001; 24(4): 654 - 658. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. S. Djurhuus, A. Vaag, and N. A. H. Klitgaard Muscle Sodium, Potassium, and [3H]Ouabain Binding in Identical Twins, Discordant for Type 2 Diabetes J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 859 - 866. [Abstract] [Full Text]
|
|
|
|
|
|
D. S.H. Bell, T. W. Gress, F. L. Brancati, J. R. Sowers, and G. L. Bakris Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus N. Engl. J. Med., August 24, 2000; 343(8): 580 - 581. [Full Text]
|
|
|
|
|
|
M. L. Kukin, J. Kalman, R. H. Charney, D. K. Levy, C. Buchholz-Varley, O. N. Ocampo, and C. Eng Prospective, Randomized Comparison of Effect of Long-Term Treatment With Metoprolol or Carvedilol on Symptoms, Exercise, Ejection Fraction, and Oxidative Stress in Heart Failure Circulation, May 25, 1999; 99(20): 2645 - 2651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Carlson and K. Oberg Clinical Pharmacology of Carvedilol Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1999; 4(4): 205 - 218. [Abstract] [PDF]
|
|
|
|
|
|
S. S. Gottlieb, R. J. McCarter, and R. A. Vogel Effect of Beta-Blockade on Mortality among High-Risk and Low-Risk Patients after Myocardial Infarction N. Engl. J. Med., August 20, 1998; 339(8): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
